Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zim LaboratoriesNSE:ZIMLAB +1.99%79 Debt-to-Equity is 0.43 as of Mar. 2026, which is 12% below its 10-year median of 0.49. GuruFocus rates NSE:ZIMLAB with a GF Score™ of 79/100 and a GF Value™ of ₹101.97 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 812 Drug Manufacturers companies, Zim Laboratories ranks worse than 63.92% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Zim Laboratories's Debt-to-Equity or its related term are showing as below:
NSE:ZIMLAB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.3 Med: 0.49 Max: 0.68
Current: 0.43
During the past 12 years, the highest Debt-to-Equity Ratio of Zim Laboratories was 0.68. The lowest was 0.30. And the median was 0.49.
NSE:ZIMLAB's Debt-to-Equity is ranked worse than 63.92% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs NSE:ZIMLAB: 0.43
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Zim Laboratories Debt-to-Equity Related Terms
Zim Laboratories Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Zim Laboratories's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ZIMLAB vs ZTS, UTHR: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zim Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zim Laboratories Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zim Laboratories's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Zim Laboratories's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zim Laboratories (NSE:ZIMLAB) has a Debt-to-Equity of 0.43 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zim Laboratories and its competitors. This is 12% below median its historical median of 0.49. Over the past decade, Zim Laboratories' Debt-to-Equity has ranged from 0.30 to 0.68. According to the industry distribution chart, Zim Laboratories ranks #519 out of 812 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Zim Laboratories' Debt-to-Equity too high?
Zim Laboratories' current Debt-to-Equity of 0.43 is 12% below median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 0.68. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Zim Laboratories' value of 0.43 is 59.3% above this industry median. Based on the distribution chart, Zim Laboratories ranks #519 out of 812 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Zim Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zim Laboratories' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Zim Laboratories ranks #519 out of 812 companies for Debt-to-Equity. This places Zim Laboratories in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Zim Laboratories' value of 0.43 is 59.3% above this benchmark. Historically, Zim Laboratories' own Debt-to-Equity has ranged from 0.30 to 0.68 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 0.27, Zim Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zim Laboratories's current Debt-to-Equity of 0.43 is 59.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Zim Laboratories and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zim Laboratories's current Debt-to-Equity is 0.43, which is 12% below median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zim Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Zim Laboratories (NSE:ZIMLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹101.97, compared to a current price of ₹118.20 — trading 15.9% above its estimated fair value. The current Debt-to-Equity is 0.43, which is 12% below median its 10-year median of 0.49 and 59.3% above the Drug Manufacturers industry median of 0.27. Zim Laboratories' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Zim Laboratories (NSE:ZIMLAB), the current Debt-to-Equity is 0.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zim Laboratories (NSE:ZIMLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zim Laboratories stock appears to be overvalued.
The current stock price of ₹118.20 is trading 15.9% above its estimated GF Value™ of ₹101.97.
GuruFocus considers Zim Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:ZIMLAB:
Debt-to-Equity: 0.43 (12% below median its 10-year median of 0.49)
GF Value™: ₹101.97 vs. price of ₹118.20 (15.9% above fair value)
Industry Position: 59.3% above the Drug Manufacturers median (#519 of 812)
No single metric tells the full story. See the NSE:ZIMLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zim Laboratories Ltd is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India. It is engaged in manufacturing &wholesale of pharmaceutical products, market research and research & development activities. The Group is mainly engaged in the business of pharmaceuticals. It has presence in India and Outside India. The company generates majority of revenue from India. Its products are Oral Thin Films, Pre-formulations Intermediates, Finished Formulations.
79GF Score
Get the complete analysis for NSE:ZIMLAB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ZIMLAB has been successfully added to your 
